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Abstract
Gingival fibromatosis is a rare and heterogeneous group of disorders that develop as slowly progressive, local or diffuse
enlargements within marginal and attached gingiva or interdental papilla. In severe cases, the excess tissue may cover the
crowns of the teeth, thus causing functional, esthetic, and periodontal problems, such as bone loss and bleeding, due to
the presence of pseudopockets and plaque accumulation. It affects both genders equally. Hereditary, drug-induced, and
idiopathic gingival overgrowth have been reported. Hereditary gingival fibromatosis can occur as an isolated condition or
as part of a genetic syndrome. The pathologic manifestation of gingival fibromatosis comprises excessive accumulation of
extracellular matrix proteins, of which collagen type I is the most prominent example. Mutation in the Son-of-Sevenless-1
gene has been suggested as one possible etiological cause of isolated (non-syndromic) hereditary gingival fibromatosis,
but mutations in other genes are also likely to be involved, given the heterogeneity of this condition. The most attractive
concept of mechanism for drug-induced gingival overgrowth is epithelial-to-mesenchymal transition, a process in which
interactions between gingival cells and the extracellular matrix are weakened as epithelial cells transdifferentiate
into fibrogenic fibroblast-like cells. The diagnosis is mainly made on the basis of the patient’s history and clinical
features, and on histopathological evaluation of affected gingiva. Early diagnosis is important, mostly to exclude
oral malignancy. Differential diagnosis comprises all pathologies in the mouth with excessive gingival overgrowth.
Hereditary gingival fibromatosis may present as an autosomal-dominant or less commonly autosomal-recessive mode
of inheritance. If a systemic disease or syndrome is suspected, the patient is directed to a geneticist for additional
clinical examination and specialized diagnostic tests. Treatments vary according to the type of overgrowth and
the extent of disease progression, thus, scaling of teeth is sufficient in mild cases, while in severe cases surgical
intervention is required. Prognosis is precarious and the risk of recurrence exists.
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Background
Gingival fibromatosis (GF) is a rare condition character-
ized by pathological, diffuse or local growth of gingiva. In
severe cases functional, periodontal, esthetic and psycho-
logical problems may occur. The condition may be related
to hereditary factors and occurs as a non-syndromic her-
editary gingival fibromatosis (HGF) or as a part of a syn-
drome. It may also develop in susceptible individuals as a
side effect of systemic medications, including the anti-
seizure, immunosuppressant, or calcium channel blockers.
In some cases the etiology of the enlargement remains un-
known. Excessive accumulation of extracellular matrix
(ECM) components seems to contribute to the pathologic
manifestation of GF, however, the molecular mechanisms
responsible for it remain undefined. The risk of recurrence
and lack of non-invasive therapies for GF used in dental
practice highlight the necessity of searching for novel al-
ternate therapies for this condition. The aim of this article
is to present an updated review of the clinical features, eti-
ology, differential diagnosis, pathological mechanisms and
management of GF.
Review
Disease name and synonyms
GF is also called gingivomatosis, gingival enlargement, gin-
gival hyperplasia, gingival overgrowth (GO), elephantiasis
gingivae, familial elephantiasis, gigantism of the gingiva,
and congenital macrogingivae [1].
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Definition
GF is a condition characterized by the pathological growth
of gingival tissue. It is also described as “gingival enlarge-
ment”, which comprises gingival hyperplasia and hyper-
trophy. Hyperplasia refers to an increased number of cells,
and hypertrophy refers to an increase in the size of the in-
dividual cells. GF can present as HGF, which may appear
as an isolated entity or as part of a genetic disease or syn-
drome, as drug-induced gingival overgrowth (DIGO, GO)
or as idiopathic gingival fibromatosis (IGF).
Epidemiology
GF associated with hereditary factors (non-syndromic)
HGF (GINGF, ORPHA 2024, MIM 135300) is a rare dis-
ease with unknown prevalence [2–4] (Table 1).
GF associated with genetic diseases and syndromes
GF may also co-exist with rare genetic syndromes and dis-
eases, i.e. GF with craniofacial dysmorphism (ORPHA
2025, MIM 228560) [5], GF with progressive deafness
(ORPHA 2027, MIM 135550) [6], infantile systemic hyali-
nosis (ISH, ORPHA 2176, MIM 236490) [7], juvenile hya-
line fibromatosis (JHF, Murray-Puretic-Drescher syndrome,
ORPHA 2028, MIM 228600) [8], Zimmermann-Laband
syndrome (ZLS, ORPHA 3473, MIM 135500) [9], amelo-
genesis imperfecta/nephrocalcinosis syndrome (ORPHA
1031, MIM 204690) [10], amelogenesis imperfecta/GF syn-
drome (AIGFS, ORPHA 171836, MIM 614253) [11], and
oculodental syndrome (Rutherfurd syndrome, ORPHA
2709, MIM 180900) [12], which occur with a prevalence of
one or less per million population. The frequency of other
genetic entities that present with a periodontal phenotype,
i.e. GF/hypertrichosis syndrome (ORPHA 2026, MIM
135400) [13] and Ramon syndrome (ORPHA 3019, MIM
266270) [14], is unknown (Table 1).
DIGO
The reported incidence of GF induced by the anti-epileptic
drug, phenytoin could be as high as 70 % [15]. It also oc-
curs in 15–83 % of patients treated with nifedipine [16,
17], 21 % of patients taking diltiazem [18], and approxi-
mately 4 % of patients cured with verapamil [19], while the
prevalence rate of gingival enlargement in patients treated
with cyclosporine A (CsA) is estimated at between 8 and
70 % [20–22].
IGF
IGF is known to affect 1 in 750,000 individuals, and can
occur in both genders and in either of the jaws [1, 23, 24].
Clinical description
The most common form of GF occurs as a benign, slowly
progressive and non-hemorrhagic enlargement of the gin-
giva. It affects the masticatory mucosa (the marginal and
attached gingiva and the interdental papilla), but it does
not spread beyond the muco-gingival junction. GF can be
generalized, idiopathic or hereditary (non-syndromic)
(Figs. 1a and 2a) or associated with different genetic dis-
eases. Clinically, the onset coincides with the eruption of
primary or permanent dentition, and rarely presents at
birth [25]. GF may also occur as a local, nodular-like le-
sion. The excess gingival tissue can cover part of or the
entire crown, and can result in diastemas, teeth displace-
ment, or retention of primary or impacted teeth, and may
also cause masticatory, phonetic, psychological, and es-
thetic problems [26]. An example of a local, nodular-
like lesion in the posterior maxillary region of the gin-
giva in a 35-year-old patient diagnosed as an IGF is
depicted in Fig. 3a. Clinical features of isolated HGF,
and genetic syndromes and diseases co-existing with
HGF are presented in Table 1. DIGO usually occurs as
a generalized (diffuse) enlargement usually visible
within several months after the onset of systemic ther-
apy. This is in contrast to HGF, which is characterized
by a slow, progressive growth of the gingival tissue.
GO may vary from mild to severe, depending on the
dose of the drug. Combination therapy, such as with
amlodipine, a calcium channel blocker used in the
management of hypertension and angina, and
cholesterol-lowering drugs, can result in more severe
GO than single-agent therapy [17]. Although the clin-
ical appearance of lesions resulting from different
medications is similar, the histopathology of DIGO le-
sions varies depending on the inducing drug [27]. Hy-
perplastic gingiva usually presents a normal coloration
or can be erythematous. Periodontal problems, such as
bleeding and bone loss, might occur due to the excess
of gingival tissue, presence of pseudopockets and
plaque accumulation [17, 28–30].
Histopathological description
The typical histopathology of the lesion involves hyperpla-
sia of the epithelium with elongated rete ridges extending
into the underlying connective tissue [31–34] (Figs. 1b
and 2b). The connective tissue consists of excess collagen,
but has relatively few fibroblasts and blood vessels [35, 36]
(Fig. 1b). Enlarged fibroblasts appear to alternate with thin
and thick collagen fibrils. Elastic and oxytalan fibers are
also present in GF lesions. Unlike in normal gingiva,
coarse and fine dense collagen fiber bundles are oriented
in all directions [32, 33, 37] (Fig. 3b). Small osseous calcifi-
cations and abundant neurovascular bundles may also be
present. The excess of gingival tissue may provide new
niches for the growth of microorganisms, plaque accumu-
lation and pseudopockets formation resulting in inflam-
matory infiltration of the gingival connective tissue [17,
38–41] (Fig. 2b).
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Table 1 Characteristics of HGF (non-syndromic) and its co-existence with rare genetic diseases and syndromes






Age of onset Clinical hallmarks
Hereditary gingival
fibromatosis, HGF, ORPHA
2024, MIM 135300 [4]
Autosomal dominant gingival fibromatosis,
Autosomal dominant gingival hyperplasia,
Hereditary gingival hyperplasia
unknown GINGF All ages Slowly progressive hyperplasia of the
maxillary and mandibular gingiva.
Occurs with eruption of the permanent
teeth, more rarely with the primary

























unknown unknown Neonatal Gingival fibromatosis, macrocephaly,
bushy eyebrows with synophrys,
hypertelorism, downslanting palpebral
fissures, flattened nasal bridge, hypoplastic




2027, MIM 135550 [6]




unknown unknown Adults Gingival fibromatosis, progressive
sensorineural hearing loss [168, 169].
Gingival fibromatosis/
hypertrichosis syndrome,
HTC3, ORPHA 2026, MIM
135400 [13]
Congenital generalized hypertrichosis terminalis
(CGHT), Hirsutism/congenital gingival hyperplasia
syndrome, Hypertrichose avec ou sans hyperplasie













occurring at birth or during childhood,
hirsutism, generalized hypertrichosis
predominantly affecting the face, upper
limbs and midback [170–175].
Ramon syndrome, ORPHA





unknown unknown Infancy Gingival fibromatosis, cherubism (fibrous
dysplasia of the maxilla and mandible),
delayed tooth eruption, narrow palate,
short stature, kyphosis, scoliosis, mental



















Gingival fibromatosis, delayed tooth
eruption, prominent mandible, high
arched palate, broad nasal bridge, thick
lips, thick eyebrows, synophrys, myopia,
cataracts, cardiomyopathy, hepatomegaly,
splenomegaly, scoliosis, hyperextensible
fingers, hypoplastic distal phalanges,
















Table 1 Characteristics of HGF (non-syndromic) and its co-existence with rare genetic diseases and syndromes (Continued)
Infantile systemic hyalinosis








4q21.21 [185, 186] ANTXR2*
[187, 188]
Childhood Gingival fibromatosis, osteolysis,
osteoporosis, osteopenia, recurring
subcutaneous tumors, recurrent infections,
joint contractures, diarrhea [185–191].
Juvenile hyaline fibromatosis







2709, MIM 180900 [12]
Gingival hypertrophy/ Corneal dystrophy,








Gingival fibromatosis, delayed primary
teeth eruption, failure of secondary teeth




ORPHA 1031, MIM 204690**
[10]
Enamel - renal syndrome (ERS), Enamel -

















fibromatosis, delayed tooth eruption, thin
hypoplastic or absent enamel,
microdontia and spaced teeth, intra-
pulpal calcifications, root dilacerations of
impacted teeth [154, 195, 196, 198]. Renal
phenotype: bilateral medullary nephrocal-
cinosis, focal clusters of sclerosed glom-
eruli, marked periglomerular fibrosis with
lymphocytic and plasma cell infiltration of




171836, MIM 614253** [11]
MIM, Mendelian Inheritance in Man; *SOS-1, Son-of-Sevenless-1; *CAMK, calcium/calmodulin-dependent protein kinase IV; *ABCA5, ATP-binding cassette, subfamily A, member 5; *KCNH1, potassium channel, voltage-
gated, subfamily H, member-1; *ANTXR2, anthrax toxin receptor 2; *FAM20A, family with sequence similarity 20, member A.
**Considering the significant overlap in the oral phenotype between cases with amelogenesis imperfecta (AI) with hamartomas and unerupted teeth, amelogenesis imperfecta/gingival fibromatosis syndrome (AIGFS),
and enamel-renal syndrome (ERS) in the published literature as well as the pathognomonic character of the oral phenotype in the absence of other developmental health problems, the two OMIM entries for ERS and
















Diseases associated with “gingival enlargement”
Gingival enlargement covers broad etiological entities clas-
sified into five general groups:
1. Enlargement associated with non-genetic diseases
GF can be directly or indirectly linked to poor
nutrition (vitamin C deficiency) [42], systemic
hormonal stimulation (pregnancy or puberty) [43],
blood dyscrasias (leukemia) [44–47], Wegener’s
granulomatosis [48], orofacial granulomatosis [49],
pyogenic granuloma [50] and sarcoidosis [51]. It
may also be associated with pseudotumors [52, 53],
benign neoplasms, e.g. giant cell fibroma [54],
gingival and oral myofibroma [55–57], papilloma [58],
giant cell granuloma [59], and malignant neoplasms,
e.g. oral squamous cell carcinoma [60, 61], salivary
gland tumors [62, 63], melanoma [64–67], adenoma
and mucoepidermoid carcinoma [68].
2. Enlargement associated with inflammatory diseases
of the oral cavity
Gingival enlargement may develop during the course
of inflammatory diseases of the oral cavity, for example
localized and generalized aggressive periodontitis (AP)
and primary gingival tuberculosis [69–73]. Plaque
Fig. 1 Diffuse, hereditary gingival fibromatosis in a 13-year-old female
reported to the Department of Periodontology and Oral Medicine,
Jagiellonian University, Collegium Medicum, Krakow, Poland. a Clinical
appearance of the lesion before surgery. b Epithelial acanthosis, dense
connective tissue consisting of numerous collagen fiber bundles, a
moderate amount of fibroblasts, and scanty blood vessels in tissue
sections stained by hematoxylin and eosin, original magnific. 100×.
Histological staining was performed at the Microbiology Department,
Jagiellonian University, Krakow, Poland
Fig. 2 Non-syndromic, diffuse, hereditary gingival fibromatosis in a
32-year-old female treated at the Department of Periodontology and
Oral Medicine, Jagiellonian University, Collegium Medicum, Krakow,
Poland. a Recurrence at 1 year post-surgery is visible in the anterior
region of the mandibula. b Hematoxylin and eosin staining shows
epithelial acanthosis and atypically abundant inflammatory infiltrates
distributed in the subepithelial and connective tissue, original magnific.
100×. Histological staining was performed at Microbiology Department,
Jagiellonian University, Krakow, Poland [41]
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accumulation and bacterial infection resulting
from poor oral hygiene are significant predisposing
factors [41, 74]. Other examples are inflammatory
pseudotumors [53] and inflammatory fibrous
hyperplasia due to local irritants [75].
3. Enlargement associated with hereditary factors and
co-existing with genetic diseases and syndromes
[4, 9–14, 25, 35, 41]
4. Drug-induced gingival enlargement [15–18, 20, 39]
5. Gingival enlargement of unknown etiology [1, 37,
40, 76]
Etiology
GF associated with hereditary factors (non-syndromic and
associated with genetic diseases and syndromes)
HGF (ORPHA 2024, MIM 135300) is a rare and slowly
progressive condition characterized by etiological het-
erogeneity [4, 23, 29, 41, 77]. Additionally, it may co-exist
with several genetic diseases or syndromes (Table 1).
Moreover, it may occur sporadically in several other syn-
dromes and diseases. An example is Cowden syndrome
(multiple hamartoma syndrome, CWS1-6, ORPHA201,
MIM 158350) [78], a rare autosomal dominant disorder
characterized by multiple hamartomas and a high risk of
development of malignancy. It is now believed that 25 %
of CWS cases (CWS1) are caused by germline mutations
in the phosphatase and tensin homolog (PTEN) gene
(10q23), which encodes PTEN, a dual-specificity phos-
phatase. Patients with CWS and CWS-like phenotypes
without PTEN involvement have been found to have
germline promoter methylation of KLLN (10q23; CWS4)
(30 % of cases); germline variations in SDHB (1p36;
CWS2), SDHC or SDHD (11q23; CWS3) (10 % of cases);
or germline mutations in AKT1 (14q32; CWS6) or
PIK3CA (3q26; CWS5) (10 % of cases) [79–82]. The most
predominant features of the syndrome are small papular
cutaneous lesions, papillomatous outgrowth, and fibromas
of the oral mucosa and tongue [83, 84]. The co-existence of
gingival hyperplasia with Cowden syndrome was reported
by two groups [85, 86]. Another example is Bardet-Biedl
syndrome (BBS1-19, ORPHA 110, MIM 209900) [87], a
rare, heterogeneous, oligogenic or autosomal recessive con-
dition with a prevalence in Europe estimated at between 1/
125,000 and 1/175,000. Clinical features include obesity,
pigmentary retinopathy, post-axial polydactyly, polycystic
kidneys, hypogenitalism, and learning disabilities, many of
which appear several years after disease onset. The clinical
expression is variable, but most patients exhibit the ma-
jority of these clinical features during the disease course
[88–91]. Dental anomalies, regarded as secondary mani-
festations, include hypodontia, microdontia, short roots,
and a deep palate. The first case of BBS with generalized
GO was reported by Drugowick et al. [92]. An example of
a disease where genetic and infective factors are involved
is AP. It is a rare, severe, and rapidly progressive form of
periodontitis that develops as a result of complex interac-
tions between specific host genes and the local micro-
environment of the oral cavity. Factors which increase the
risk of AP development include: familial aggregation, sin-
gle nucleotide polymorphisms, functional defects in neu-
trophils, antibodies to specific bacteria, herpes virus
infection, stress and smoking [69]. Though GF and AP
usually occur as separate entities, several reports describe
the co-existence of these diseases. The first report was
published by Mahajan et al. [70], followed by reports by
Jadwat et al. [71], Chaturvedi [93], Sandhu et al. [94], and
Vishnoi and Phadnaik [72]. Recently, Ramachandra et al.
[95] reported a case of gingival enlargement associated
with generalized AP and the presence of mesiodens. The
common features of GF and localized AP are their onset
around puberty, female predilection, hereditary back-
ground, and progression in the presence of minimal local
factors, although secondary involvement can aggravate the
pre-existing condition [96].
Fig. 3 Idiopathic gingival fibromatosis in the posterior maxillary region of the gingiva of a 35-year-old patient treated at the Department of
Periodontology and Oral Medicine, Jagiellonian University, Collegium Medicum, Krakow, Poland. a Clinical image of the lesion before surgery.
b Numerous bundles of collagen fibrils oriented in antithetic directions in the dense, thick connective tissue, visualized by Heidenhain’s trichrome
staining, original magnific. 100×. Histological study was conducted at Microbiology Department, Jagiellonian University, Krakow, Poland [37]
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HGF may be transmitted as a Mendelian trait in an auto-
somal dominant or, less commonly, an autosomal recessive
fashion [29]. Linkage analysis has provided clues about the
etiology of the disease, and showed several chromosomal
regions that may contain mutations responsible for HGF.
Loci for isolated, non-syndromic autosomal dominant
forms of HGF have been localized to chromosome 2p21-
p22 in a Brazilian family [97], and to chromosome 5q13-
q22 [98] and 11p15 in a number of Chinese families [99].
The candidate loci are GINGF, GINGF2 and GINGF4,
respectively.
After sequencing 16 genes in the candidate interval
(2p21-p22), a single base insertion in the Son-of-Sevenless-
1 (SOS-1) gene (MIM 182530) underlying GINGF locus,
was detected in a Brazilian family [100], but not in three
Chinese families [101]. Similar to the observations of Ma et
al., our recent study did not confirm the presence of a sin-
gle nucleotide insertion in the SOS-1 gene in two Polish
families diagnosed with non-syndromic HGF (unpublished
data). Interestingly, in four other Chinese families, non-
syndromic HGF was linked to a mutation in the 2p21 locus
(GINGF), as previously reported by Hart et al. [97]. A mu-
tation in the SOS-1 gene has been suggested as one pos-
sible etiological factor/causing gene for isolated, non-
syndromic HGF, but considering the genetic heterogeneity
of HGF, mutations in other genes are also likely to be
involved.
By haplotype construction and analysis in a five-
generation Chinese family segregating autosomal domin-
ant HGF, Ye et al. [102] identified a novel locus, which
they designated GINGF3, in an 11.4 cM interval between
markers D2S2221 and D2S1788 on chromosome 2p23.3-
p22.3. Authors noted that this locus is distal to and does
not overlap with the previously described GINGF locus
on 2p22-p21 [102].
DIGO
Drug-induced GF occurs in susceptible individuals as a
side effect of systemic medications, including the anti-
epileptic drug phenytoin, the immunosuppressant CsA,
and calcium channel blockers, namely, dihydropyridines,
particularly nifedipine, diltiazem, and verapamil, which
are widely used to control hypertension [103, 104]. Cur-
rently, more than 20 drugs are associated with gingival
enlargement [17, 105]. Although the drugs that can
cause GO have distinct mechanisms of action and act on
different primary target tissues, they all seem to have a
similar adverse effect on the gingival connective tissue
[22, 104, 106]. In addition to being disfiguring, GO may
also lead to poor oral hygiene and decreased oral func-
tion in individuals already suffering from conditions such
as epilepsy, cardiovascular diseases, or immunosuppression
[107]. The pathogenesis of DIGO is dependent on several
factors, such as: age, genetic predisposition, pharmacokinetic
variables, alterations in gingival connective tissue homeosta-
sis, pre-existing dental plaque and gingival inflammation,
and interaction of drugs and growth factors [106, 108, 109].
Pathogenesis and Pathophysiology
The pathologic manifestation of GF is excessive accumula-
tion of ECM proteins, including collagen type I [110–114].
Thus far, however, the molecular and biochemical mecha-
nisms that trigger this pathological process are not com-
pletely understood.
During collagen biosynthesis, nascent single procollagen
polypeptides undergo post-translational modification in
the endoplasmic reticulum (ER), form triple-helical chains,
and are secreted into the extracellular space. This process
involves heat shock protein 47 (HSP47), a 47 kDa glyco-
protein localized in the ER. It binds to the nascent type I
procollagen peptides to prevent premature folding and ag-
gregation of procollagen chains, and participates in the
translocation and secretion of procollagen I into the extra-
cellular space [115]. Type I collagen and HSP47 mRNA
and protein levels are increased significantly in fibroblast
cultures derived from patients with HGF [116]. Moreover,
transforming growth factor (TGF)-β1 and interleukin
(IL)-6 induce the expression of type I collagen and HSP47
and to downregulate matrix metalloproteinase (MMP)-1
and MMP-2 in fibroblast cultures from HGF patients. The
effect of TGF-β1 and IL-6 on the synthesis of other ECM
proteins was also reported in DIGO [112, 117–120]. By
contrast, interferon-γ (IFN-γ) reduced collagen I and
HSP47 expression, and it slightly affected MMP-1 and
MMP-2 expression [116]. This observation suggests that
HSP47 may be a crucial molecule in the post-translational
processing of the overproduced type I procollagen chains,
while enhanced TGF-β1 and IL-6 production in patients
with GF may favor the accumulation of collagen fibrils in
the gingiva.
Prolyl 4 hydroxylases (P4Hs) are equally essential en-
zymes in the biosynthesis and folding of newly-synthesized
collagen polypeptide chains into triple-helical molecules
[121]. P4Hs are α2β2 tetramers consisting of one of three
isoforms of subunit α [α(I), α(II), or α(III)] that have similar
catalytic activity [122]. The expression of the α subunit of
P4Hs limits the rate of active P4H formation, P4H activity,
and collagen synthesis [123]. Increased levels of P4H activ-
ity are reported in a number of fibrotic conditions such as
keloids and hepatic fibrosis [124, 125]. Some studies report
increased expression and activity of prolyl hydroxylases in
IGF, DIGO, and HGF [126, 127]. Notably, Meng et al.
[127] identified isoform I of the α subunit of P4Hα as the
isoform associated with GO, while the type II and III forms
of P4H were not affected. These findings suggest that
P4Hα (I) might be involved in the pathogenesis of HGF
and confirm that HGF fibroblasts are deregulated at the
level of post-translational protein modification.
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Alterations in the expression of MMPs, key enzymes
regulating the composition of the ECM, have been im-
plicated in the pathogenesis of GF. Several studies show
a significant decrease in the expression and activity of
MMP-1 and MMP-2 in fibroblasts from HGF patients in
comparison with controls [116, 128]. MMP-1 is a colla-
genase that degrades interstitial collagen, while MMP-2
acts predominantly on type IV collagen, but it has also
been shown to degrade type I collagen in its native form
[129]. Similarly, the inhibition of MMP-1, MMP-2, and
MMP-3 has been reported in CsA-induced GO, a condi-
tion also associated with enhanced TGF-β1 production
[114, 130, 131]. The catalytic activity of the MMPs is
regulated at the transcriptional level as well as by tissue
matrix metalloproteinase inhibitors (TIMPs). Interest-
ingly, addition of anti-TGF-β1 antibodies in the study by
Coletta et al. [128] resulted in a slight increase in MMP-
1 and a decrease in MMP-2 expression, whereas TIMP-1
and TIMP-2 expression were unaffected. These results
confirm previous observations that enhanced TGF-β1
production may lead to the accumulation of ECM by al-
tering the proteolytic activities of fibroblasts.
Systemic therapy with CsA, phenytoin, and nifedipine
modulates cytokine levels and indirectly affects gingival
connective tissue metabolism. For example, Hong and
Trackman [132] observed that the mRNA expression of
lysyl oxidase and collagen type I by human gingival fibro-
blasts decreased to 53 % and to less than 10 % of control
levels, respectively, after 48 h of treatment with 1 nM
basic fibroblast growth factor (bFGF), while lysyl oxidase
enzymatic activity was downregulated by 10–20 %. By
contrast, interleukin - 1 (IL-1), IL-6, and platelet-derived
growth factor-BB (PDGF-BB) did not significantly regulate
the enzymatic activity of lysyl oxidase or the mRNA levels
of lysyl oxidase, collagen type I or elastin [132]. The op-
posite effect was found by stimulation of gingival fibro-
blasts with TGF-β1. In brief, TGF-β1 upregulated lysyl
oxidase and collagen type I, but not elastin, in a dose- and
time-dependent manner. The maximal effect on lysyl oxi-
dase activity and mRNA expression, as well as the mRNA
expression of collagen I occurred after 48 h of treatment
of gingival fibroblastic cells with 400 pM TGF-β1.
It has also been shown that mRNA and protein syn-
thesis of connective tissue growth factor (CTGF or
CCN2) are significantly induced by TGF-β1 in human
gingival fibroblasts [133]. CTGF/CCN2 is a member of
the CCN family, members of which contain conserved
cysteine-rich domains and have a variety of biological
activities [134]. CTGF promotes the proliferation of vari-
ous cell types [135, 136] and is highly expressed in a wide
variety of fibrotic lesions, including skin and kidney fibro-
sis, and atherosclerosis [137–139]. Uzel et al. [27] assessed
the expression and localization of CTGF in GO induced
by three different systemic medications. CTGF expression
was significantly higher in phenytoin-induced GO than in
CsA- or nifedipine-induced GO. Similar observations are
reported by Hong et al. [133]. Considering that
phenytoin-induced lesions are more fibrotic than nifedi-
pine- and CsA-induced lesions, it seems that CTGF levels
correlate positively with fibrosis and have a role in pro-
moting and maintaining fibrosis. Development of fibrotic
events can involve the process known as epithelial/mesen-
chymal transition (EMT). It occurs physiologically during
organ and tissue development. In this process, partial de-
struction of the basement membrane can lead to inappro-
priate diffusion of factors between the connective tissue
and the epithelial layers of gingival tissues. These factors
can stimulate epithelial cells to lose cell-cell contacts, de-
crease E-cadherin expression, and increase cell motility,
promoting their invasion into the underlying connective
tissue stroma, where they differentiate further into cells
that are indistinguishable from fibroblasts and myofibro-
blasts. These fibroblastic cells, in turn, produce connective
tissue proteins that contribute to fibrosis [140–142].
Diagnosis
A diagnosis of GF is made mainly on the basis of clinical
and periodontal examination, a medical and family his-
tory and laboratory tests. Clinical examination, medical
history and laboratory tests determine initially whether
the condition is inherited or acquired, the presence of
other diseases, the prior therapies used, and the involve-
ment of primary dentition. Histopathological analysis
characterizes the typical features of fibromatotic gingiva,
such as the rate of epithelial acanthosis, connective tis-
sue density and cellular content, the extent of fibrosis or
inflammatory infiltrates. Periodontal examination, in-
cluding X-ray and histopathology serve mainly to assess
the type (local, diffuse, fibrous or inflammatory) and the
severity of gingival involvement, including bone erosion,
and allow the physician to choose the optimal treatment
option [143–146].
Differential diagnosis
If a genetic background is found, it is important to verify
whether the lesion is an isolated entity or occurs as part
of a multisystem pathology. The list of the syndromes
associated with periodontal involvement is presented in
Table 1. Particularly important are neoplasms, though be-
nign tumors and pseudotumors can given similar patterns
of clinical involvement [52]. Amongst benign tumors of
the gingiva, giant cell fibroma, irritation fibroma, neuro-
fibroma, angiofibroma (tuberous sclerosis or Bourneville-
Pringle disease), inflammatory myofibroblastoma and
epulis fissuratum should be considered. Epulis fissuratum is
a specific condition usually found in patients with remov-
able full dentures. Inflammatory myofibroblastoma ranges
from completely benign to malignant tumors with a fatal
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outcome [53–57, 147, 148]. Malignant neoplasms which
have to be considered are oral squamous cell carcinoma
[60, 61], salivary gland adenocarcinoma [62, 63], melanoma
64–67], adenoma and mucoepidermoid carcinoma [68]. Re-
garding DIGO, it may occur not only for calcium channel
blockers, CsA and phenytoin but also with other immuno-
suppressants or anticonvulsants, antibiotics, and oral con-
traceptives [149]. Differential diagnosis of GF with
granulomatous lesions includes systemic diseases such as
sarcoidosis, Crohn’s disease, and tuberculosis, as well as le-
sions localized to the orofacial region like orofacial granulo-
matosis [48, 49, 51, 150]. Although leukemia is a malignant
disease of the blood, where the uncontrolled proliferation
of immature blood cells takes place, leukemic infiltration of
oral tissues may occur, resulting in a pale mucosa, poor
wound healing, and bleeding, which in some cases can re-
semble GF [45, 46]. Lymphomas rarely manifest initially in
the oral cavity, but misdiagnosis is highly probable because
maxillary and mandibular swelling can mimic fibrotic lesion
[47, 151]. All these conditions require thorough analysis of
medical history, laboratory tests, and histopathology as a
delay in the diagnosis, particularly in the case of malignancy
may worsen the prognosis.
Genetic counseling
HGF may present as an autosomal-dominant or less com-
monly autosomal-recessive mode of inheritance, as an iso-
lated disorder or as part of a syndrome [4, 9, 10, 13, 152].
Autosomal dominant forms are usually isolated (non-syn-
dromic) and have been genetically linked to several loci,
i.e. GINGF, GINGF2, GINGF3, GINGF4 [97–100, 102]
(Table 1). If clinical/periodontal examination, family his-
tory and laboratory tests initially indicate a genetic back-
ground, other family members are called to the clinic to
confirm the presence of HGF, draw up a pedigree diagram,
and determine whether it constitutes an isolated entity or
co-exists with another disease or syndrome. If a systemic
disease or syndrome is suspected, the patient is directed
to a geneticist for additional clinical examination and spe-
cialized diagnostic tests. In such cases psychological sup-
port is needed to assess a risk of occurrence in future
pregnancies, the option of early prenatal diagnosis and op-
timal treatment.
Management including treatment
The patient’s medical history (e.g. patient’s age and the
presence of other diseases) and the findings of the clinical
examination (e.g. the type and severity of overgrowth) in-
fluence the patient’s management. While some surgical
approaches, such as the use of laser excision, reportedly
reduce the recurrence, re-growth of the excised gingival
tissue due to the continuous use of the drug presents a
significant challenge [153]. The usual treatment of GF in-
cludes external bevel gingivectomy using a scalpel, unless
this is complicated by bony defects, in which case, a flap
surgery is carried out. The surgery is followed by 0.12 %
chlorhexidine oral rinses twice a day for 2 weeks. Removal
of the hypertrophic tissue can be also done by electrosur-
gery or by laser, reducing the risk of bleeding and pain.
This type of procedure decreases significantly the quantity
of local anesthetic used, leads to better visibility, which re-
duces the chairside time, and results in better patient ac-
ceptance [74, 154, 155]. Non-surgical treatment includes
scaling and root planing, oral hygiene instructions and ad-
ministration of antibiotics, usually amoxicillin and metro-
nidazole, along with anti-inflammatory (ibuprofen) and
analgesic (paracetamol) drugs and the use of chlorhexi-
dine mouth rinses. At the end of the fourth week, internal
bevel gingivectomy along with open flap debridement is
carried out. This procedure eliminates the pocket, reduces
the bulk of the tissue and makes plaque control much eas-
ier. Management of patients diagnosed with GF and AP
includes non-surgical treatments, surgery with regenera-
tive or resective therapy and anti-microbial treatment. Re-
generative techniques include the use of bone grafts,
barrier membranes, wound healing agents and enamel
matrix protein. Local drug delivery, full mouth disinfection
and host immune response modulation are other modes of
treatment [38, 72, 76, 95, 156–158].
Because of difficulties in the treatment of DIGO, the sta-
tus of oral health prior to and during drug administration,
in combination with drug serum levels and the duration
of therapy, are key factors in the management of the con-
dition. Discontinuing or dramatically lowering the dose of
the drug often results in resolution of clinical signs and le-
sions. However, this is not always medically feasible, par-
ticularly in whole-organ transplant recipients.
Evidence suggests that 34 % of cases demonstrate re-
currence during the 18 months following periodontal
surgery regardless of the drug [156]. Although GO le-
sions are not directly life-threatening and may be toler-
ated by some patients without treatment, the quality of
life is clearly compromised among affected individuals.
Therefore, to stabilize the long-term outcomes and alle-
viate suffering for those who are adversely affected,
non-surgical therapies to treat GO are of importance.
Although progress in the clinical management of hu-
man GO has been made in relatively affluent societies,
approaches of drug substitutions and careful dose ad-
justments are not universally practiced by physicians
worldwide, and this contributes to the global public
health impact of GO [157, 159].
Prognosis
Complications related to GF include difficulties with
mastication, speech problems, displacement of teeth, es-
thetic effects, and psychological difficulties for the pa-
tient; therefore, appropriate treatment and postoperative
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management are crucial. Gingival enlargement as a form
of periodontal tissue reaction may impose a challenge to
periodontists as well. Routine treatment of minimal and
local enlargements relies on keeping appropriate oral hy-
giene and/or root scaling, while cases of advanced, dif-
fuse gingival enlargement require surgical intervention.
Recurrence can occur several months to several years
after surgery [36, 41, 160–162].
Conclusions
GF is a rare and slowly progressive condition that is also
characterized by etiological heterogeneity. Additionally,
this condition constitutes a typical symptom of several
genetic syndromes, and it may occur sporadically in sev-
eral other syndromes and diseases, as reported recently.
By contrast, DIGO may occur as soon as several months
from the onset of systemic therapy in susceptible indi-
viduals treated with certain anti-seizure drugs, immuno-
suppressants or calcium channel blockers. Diagnosis is
made based on medical history, clinical examination,
blood tests and histopathological evaluation of affected
gingival tissue. Differential diagnosis includes consider-
ation of all pathologies in the mouth that involve exces-
sive accumulation of gingival tissue, including syndromic
HGF. In general, the histological features of GF are similar,
but phenytoin-induced GO is reported to be most fibrotic
and to express higher levels of CTGF than nifedipine- and
CsA-induced GO. Excessive accumulation of ECM compo-
nents, particularly collagen type I, seems to contribute to
the pathologic manifestation of all etiological types of GF;
however, the molecular mechanisms responsible for it re-
main undefined. Further studies concerning interactions
among medications, the innate and acquired immune re-
sponse, cytokines and growth factors, and gingival epithe-
lial and connective tissue cells are essential for a better
understanding of the detailed molecular and mechanistic
pathways controlling the unique metabolism of gingival
connective tissue. This would improve disease manage-
ment and allow the implementation of less invasive thera-
peutic methods than surgery into routine dental practice.
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